Bristol-Myers Squibb Company P/E Ratio 2007–2025
Bristol-Myers Squibb Company reported 15.08 of price-to-earnings ratio for fiscal 2025. That was 29.3% higher than fiscal 2023. Compared with fiscal 2019, the change was -38.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 15.08 | — |
| FY 2024 | — | — |
| FY 2023 | 11.66 | -43.6% |
| FY 2022 | 20.66 | +25.8% |
| FY 2021 | 16.42 | — |
| FY 2020 | — | — |
| FY 2019 | 24.67 | +91.3% |
| FY 2018 | 12.90 | -82.3% |
| FY 2017 | 73.05 | +367.9% |
| FY 2016 | 15.61 | -69.6% |
| FY 2015 | 51.42 | +53.9% |
| FY 2014 | 33.42 | +46.5% |
| FY 2013 | 22.81 | +28.0% |
| FY 2012 | 17.81 | +79.1% |
| FY 2011 | 9.95 | +15.6% |
| FY 2010 | 8.61 | +224.4% |
| FY 2009 | 2.65 | -43.7% |
| FY 2008 | 4.71 | -60.9% |
| FY 2007 | 12.05 | — |
Source: Bristol-Myers Squibb Company SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BMY 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Bristol-Myers Squibb Company reported 15.08 of price-to-earnings ratio for fiscal 2025. That was 29.3% higher than fiscal 2023. Compared with fiscal 2019, the change was -38.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Bristol-Myers Squibb Company
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBristol-Myers Squibb Company — frequently asked questions
What is Bristol-Myers Squibb Company's price-to-earnings ratio?
Bristol-Myers Squibb Company (BMY) reported price-to-earnings ratio of 15.08 for fiscal year 2025, per its SEC filings.
How has Bristol-Myers Squibb Company's price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, BMY's price-to-earnings ratio grew at roughly 1.3% per year (compound annual rate), from 12.05 to 15.08.
Where does this data come from?
Figures are computed from Bristol-Myers Squibb Company's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More BMY financial history
Full BMY fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →